fig6

Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia

Figure 6. Absence of tissue remodeling after long-term genome editing in R176Q/+ mice. (A) Picrosirius staining of transverse sections of heart from R176Q/+ mice treated with control (Con) AAV9 or gRNA-SaCas9, or WT littermate mice, at 12 months after AAV9 administration. (B) Quantification showing unaltered levels of cardiac fibrosis. (C) RT-PCR showing reduced levels of Ryr2 mRNA in hearts of R176Q/+ mice treated with gRNA-SaCas9. (D) Representation of western blots and (E) quantification thereof showing reduced RyR2 protein levels in hearts of R176Q/+ mice treated with gRNA-SaCas9. P-values based on the Kruskal-Wallis test followed by Dunn’s multiple comparison post-hoc test.

The Journal of Cardiovascular Aging

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/